In contrast, KRAS mutated tumours classified as CMS1 tended to show a longer OS compared to wild-type tumours when treated with bevacizumab (Fig. 4f; p = 0.03, HR = 0.33 [0.12–0.93], FDRbev < 0.3). Here, KRAS is linked to neoplasm.